Rossini, E.; Tamburello, M.; Abate, A.; Zini, S.; Ribaudo, G.; Gianoncelli, A.; Calza, S.; Valcamonico, F.; Suardi, N.R.; Mirabella, G.;
et al. The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study. Cells 2024, 13, 368.
https://doi.org/10.3390/cells13050368
AMA Style
Rossini E, Tamburello M, Abate A, Zini S, Ribaudo G, Gianoncelli A, Calza S, Valcamonico F, Suardi NR, Mirabella G,
et al. The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study. Cells. 2024; 13(5):368.
https://doi.org/10.3390/cells13050368
Chicago/Turabian Style
Rossini, Elisa, Mariangela Tamburello, Andrea Abate, Silvia Zini, Giovanni Ribaudo, Alessandra Gianoncelli, Stefano Calza, Francesca Valcamonico, Nazareno R. Suardi, Giuseppe Mirabella,
and et al. 2024. "The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study" Cells 13, no. 5: 368.
https://doi.org/10.3390/cells13050368
APA Style
Rossini, E., Tamburello, M., Abate, A., Zini, S., Ribaudo, G., Gianoncelli, A., Calza, S., Valcamonico, F., Suardi, N. R., Mirabella, G., Berruti, A., & Sigala, S.
(2024). The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study. Cells, 13(5), 368.
https://doi.org/10.3390/cells13050368